Clinical Trial

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative bioavailability) in healthy adults.
Protocol Amendment History 3 changes
critical Trial completed 2026-06-18
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-14
critical Recruitment opened 2026-04-04
Trial Details
NCT Number NCT07316608
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Healthy Participants
Enrollment 44 participants
Start Date 2026-03-16
Primary Completion 2026-06-05 (estimated)
Study Completion 2026-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-17